- Research works
- 55 ▲ 13% vs 2013–17
- Citations
- 506 9.3 per fractional work
- Top-10% rate
- 4.6% record average 16.5%
- Open access
- 52% world 28%
Not ranked overall: Iomedico (Germany) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Medicine, 3.8×. Every wedge is a field page.
Who are the top researchers at Iomedico (Germany)?
Ranked on the composite score, Karin Potthoff, Arnd Nusch and Jörg Sahlmann lead among researchers whose main affiliation is Iomedico (Germany).
- 1 Karin Potthoff Germany · #540,305 worldwide 72 citations · 15 works
- 2 Arnd Nusch Germany · #1,034,485 worldwide 9 citations · 17 works
- 3 Jörg Sahlmann Germany · #1,357,678 worldwide 5 citations · 16 works
- 4 Martina Jänicke Germany · #1,389,703 worldwide 6 citations · 19 works
Which keywords describe research at Iomedico (Germany)?
By fractional works in all years, weighted toward what it does more of than the world: Chemotherapy, Targeted Therapy, Metastatic Breast Cancer, Breast Cancer, Prognostic Factors, Clinical Trials, Immunotherapy and Quality of Life.
- Cancer Genomics
- KRAS Mutations
- Clinical Guidelines
- PET Imaging
- Breast Tumours
- Gene Expression
- Metastasis
- Biomarkers
- Rituximab
- ALK Inhibitors
- Genomic Profiling
- Taxanes
- Metastatic
- Palbociclib
- Neoadjuvant Therapy
- Radiotherapy
- Immunotherapy
- Prognostic Factors
- Breast Cancer
- Metastatic Breast Cancer
- Chemotherapy
- Targeted Therapy
- Clinical Trials
- Quality of Life
- Molecular Subtypes
- Clinical Practice Guidelines
- CDK4/6 Inhibitors
- Survival Analysis
- Chemotherapy-Induced Peripheral Neuropathy
- Resistance Mechanisms
- Molecular Characterization
- EGFR Mutations
- Precision Medicine
- Genetic Mutations
- Prognostic Markers
- Tumor Microenvironment
- Cetuximab
- Treatment Response
- Fluorouracil
- Genomic Instability
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Chemotherapy10▲ 26×19 topics
- Metastatic Breast Cancer6▲ 180×2 topics
- Targeted Therapy6▲ 55×4 topics
- Breast Cancer6▲ 41×8 topics
- Clinical Trials5▲ 15×9 topics
- Prognostic Factors5▲ 21×8 topics
- Quality of Life5▲ 6.7×6 topics
- Immunotherapy5▲ 13×10 topics
- Molecular Subtypes4▲ 93×2 topics
- Radiotherapy4▲ 20×8 topics
- Clinical Practice Guidelines4▲ 12×7 topics
- Neoadjuvant Therapy4▲ 30×5 topics
- CDK4/6 Inhibitors3▲ 390×1 topic
- Palbociclib3▲ 390×1 topic
- Survival Analysis3▲ 23×5 topics
- Metastatic3▲ 93×2 topics
- Chemotherapy-Induced Peripheral Neuropathy3▲ 113×1 topic
- Taxanes3▲ 113×1 topic
- Resistance Mechanisms3▲ 74×2 topics
- Genomic Profiling3▲ 54×2 topics
- Molecular Characterization3▲ 29×4 topics
- ALK Inhibitors3▲ 93×1 topic
- EGFR Mutations3▲ 93×1 topic
- Rituximab3▲ 32×2 topics
- Precision Medicine3▲ 16×4 topics
- Biomarkers3▲ 7.7×5 topics
- Genetic Mutations3▲ 9.1×6 topics
- Metastasis2▲ 13×7 topics
- Prognostic Markers2▲ 48×3 topics
- Gene Expression2▲ 7.1×2 topics
- Tumor Microenvironment2▲ 12×6 topics
- Breast Tumours2▲ 85×1 topic
- Cetuximab2▲ 51×2 topics
- PET Imaging2▲ 20×3 topics
- Treatment Response2▲ 85×1 topic
- Clinical Guidelines2▲ 13×2 topics
- Fluorouracil2▲ 118×1 topic
- KRAS Mutations2▲ 118×1 topic
- Genomic Instability2▲ 31×3 topics
- Cancer Genomics2▲ 67×1 topic
Which research topics does Iomedico (Germany) publish most on?
By volume in 2022–2025: Advanced Breast Cancer Therapies, Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies and Breast Cancer Treatment Studies.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Advanced Breast Cancer Therapies Pulmonary and Respiratory Medicine 1 works
- 2 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 1 works
- 3 Colorectal Cancer Treatments and Studies Oncology 1 works
- 4 Breast Cancer Treatment Studies Cancer Research 1 works
- 5 Cancer Genomics and Diagnostics Cancer Research 0 works
- 6 Cancer Immunotherapy and Biomarkers Oncology 0 works
- 7 Pancreatic and Hepatic Oncology Research Oncology 0 works
- 8 Gastric Cancer Management and Outcomes Pulmonary and Respiratory Medicine 0 works
- 9 HER2/EGFR in Cancer Research Oncology 0 works
- 10 Cancer Treatment and Pharmacology Oncology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Iomedico (Germany)'s research output changed?
Output in 2018–2022 was 13% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Freiburg
- University of Freiburg
- University Medical Center Freiburg
- Klinik für Frauenheilkunde
- Fraunhofer Institute for Solar Energy Systems
- Fraunhofer Institute for Applied Solid State Physics
- Max Planck Institute for the Study of Crime, Security and Law
- Max Planck Institute of Immunobiology and Epigenetics
- University of Education Freiburg
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.